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Objectives 24 
Kawasaki disease (KD) is an increasingly common vasculitis with risk of coronary artery aneurysms (CAA). The 25 
last prospective UK survey was in 1990 whereas current epidemiology, treatment patterns, and complication rates 26 
are unknown, and the aim of this study was to address that knowledge gap. 27 
Methods 28 
A British Paediatric Surveillance Unit (BPSU) survey in the UK and Ireland from 01.01.2013 to 28.02.2015 29 
ascertained demographics, ethnicity, seasonal incidence, treatment, and complication rates.  30 
Results 31 
553 cases were notified: 389 had complete KD; 46 had atypical KD; and 116 had incomplete KD, two diagnosed 32 
at post-mortem. The incidence was 4.55/100,000 children under 5 years with male: female ratio of 1.5:1, median 33 
age 2.7 years (2.5 months - 15 years). Presentation was highest in January and in rural areas. Most were White 34 
(64%); Chinese and Japanese Asians were over-represented compared to national demographics (5% v 0.8%), 35 
as were Black African or African mixed-race children (11% v 7%). 94% received intravenous immunoglobulin 36 
(IVIG). The overall CAA rate was 19%, and all-cardiac complications affected 28%. Those with CAA received 37 
IVIG later than in those without (median 10 days vs 7 days). Those under 1 year had fewer symptoms, but highest 38 
CAA rate (39%). Overall 8/512 cases (1.6%) had giant CAA; and 4/86 cases (5%) under 1 year of age developed 39 
giant CAA. Mortality from KD was 0.36%. 40 
Conclusions 41 
The UK and Ireland incidence of KD has increased. KD occurs more frequently in winter and in rural areas. Whilst 42 
delayed administration of IVIG is associated with increased risk of CAA suggesting earlier treatment might reduce 43 
complications, these high complication rates also suggest that adjunctive primary treatment may be required for 44 
the primary treatment of KD to prevent CAA, particularly in the very young.  45 
 46 
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 47 
BACKGROUND 48 
Kawasaki Disease (KD) is a self-limiting medium vessel vasculitis of unknown aetiology that typically presents in 49 
children and adolescents with fever and muco-cutaneous changes. If left untreated, 15-25% of children will develop 50 
coronary artery aneurysms (CAA); 2%–3% of untreated cases die as a result of coronary vasculitis causing myocardial 51 
ischaemia, sometimes many years later 1. The incidence of KD varies from 264 per 100,000 children under 5 years 52 
in Japan, to about 5-8 per 100,000 in England 2 3. The high rate in North East Asians, which persists after migration 53 
to countries with low incidence 4, is strong evidence for a genetic factor and there is clear evidence from genome wide 54 
association studies of an important role for genetic variants in determining susceptibility. The aetiology of KD is 55 
unknown, but seasonal variation, occurrence of epidemics and association with wind patterns would be compatible 56 
with an infectious or toxic trigger 5 6. 57 
 58 
KD is the commonest cause of acquired heart disease in children in the UK and USA 7 8. Prompt diagnosis is 59 
essential to minimize complications. Intravenous immunoglobulin (IVIG) has formed the mainstay of primary 60 
treatment following publication of a seminal clinical trial in the 1980s 9. However, IVIG-resistance occurs in up to 61 
20-40% of unselected cases and is associated with increased coronary complication rates 1 10. Recent studies 62 
and meta analyses of all published studies have suggested that addition of corticosteroids to IVIG reduces the 63 
risk of CAA, particularly in high risk patients 1 10 11. However, there is currently no reliable method to predict which 64 
patients are at risk of CAA and thus require additional treatment, as scoring systems that predict IVIG non-65 
response in Japan have not been reliable in studies in UK and North America. 66 
 67 
The last comprehensive epidemiological study of KD in the UK was undertaken by the British Paediatric 68 
Surveillance unit (BPSU) in 1990 12 13. This revealed an incidence of 3.4/100,000 children under 5 years from 69 
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January 1st to 31st December 1990; and a higher than expected coronary complication rate of 29% in those 70 
children who had received IVIG, comparable to those patients who did not receive IVIG. More recent 71 
epidemiological studies noted a higher UK incidence of 8.39-9.1/100 000 children under the age of 5 3 8, but both 72 
were limited by indirect retrospective epidemiological methodologies, and thus may not be accurate. Moreover, 73 
24% of children with KD are older than five years 14 15 16, but accurate UK epidemiological data are lacking in this 74 
age group.   75 
 76 
The incidence of KD has been reported to be increasing in many countries. Furthermore, the population 77 
demographics are changing, and there is therefore a need for updated information on KD in the UK 1 17 18. The 78 
purpose of this study was to establish the current incidence of KD in the UK, noting the seasonal variation; to assess 79 
complication rates and the factors influencing these; and to shape future management practice based on these data 80 
(Panel 1). Areas of particular interest included the potential influence of ethnicity, urbanisation, and disease outcomes 81 
in the light of recently updated clinical guidance regarding the use of corticosteroids for KD 1.  82 
 83 
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Panel 1: Summary of Kawasaki disease BPSU research questions  84 
METHODOLOGY 85 
The study used BPSU methodology for the epidemiological research surveillance, similar to the 1990 BPSU KD 86 
survey 12. Each month all paediatricians and paediatric cardiologists (list available from the Royal College of 87 
Paediatrics and Child Health and the British Congenital Cardiac Association) were contacted by email to report if 88 
they had seen a case of KD. If notified, the BPSU would then make the research team aware and a questionnaire 89 
was posted. This surveillance methodology provided an active, real-time quantitative portrait of KD in the defined 90 
population. All of the UK and Ireland were included in the study. Also included were the Channel Islands and Isle 91 
of Man. Incidence was calculated by applying the most recent resident population data from the 2011-2015 92 
Census of Population 19 and their equivalents from Ireland 20 (Census 2011 Small area population statistics, 93 
Central statistics office). 94 
Incidence: 
 What are the demographics (sex, age, ethnicity, area of residence) of those diagnosed with Kawasaki disease (KD) 
in the UK and Ireland less than 16 years old?  
 Has the incidence changed since the last survey in 1990? 
Clinical Presentation and cardiac complications: 
 How does KD first present, and what is the interval between first presentation and diagnosis?  
 What is the frequency and nature of cardiac complications detected using echocardiography within 30 days of 
developing KD?  
Clinical Management: 
 What acute treatment is being given to patients during their initial hospital presentation with KD?  
 Are treatments other than aspirin and intravenous immunoglobulin being used, and if so, has this impacted on 
outcome?  
 
Other Outcomes: 
 What is the frequency of non-cardiac complications within 30 days following KD? 
 How are patients with KD being followed up within the UK and Ireland?  
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 95 
Panel 2 KD Case definition  96 
 97 
Any infant or child up to the age of 16 years presenting for the first time in the UK or Ireland with fever of 5 or more 98 
days duration plus 4 of the following (complete KD), or plus any 3 of the following (incomplete KD) or plus 2 or 3 of 99 
the following with coronary artery changes (atypical KD): 100 
 101 
1. Conjunctivitis   Bilateral, bulbar, non-suppurative 102 
2. Lymphadenopathy   Cervical > 1.5cm 103 
3. Rash    Widespread, polymorphous. Not vesicular.  104 
4. Lips and mucosa  Red cracked lips, ‘strawberry tongue’, erythematous oral cavity  105 
5. Changes of extremities Erythema, oedema of palms and soles initially, later peeling of skin  106 
 107 
Inclusion criteria 108 
In the first year, the protocol requested the reporting of only Complete KD cases, but in the second year all cases of 109 
KD (i.e. including atypical and incomplete KD as per the aforementioned definitions) were included. Where the 110 
interpretation of clinical features was uncertain, expert panel review (RT, RMW, AR, JT, DS, PB) of the case was 111 
undertaken to ascertain by consensus (defined as 100% agreement among experts) if the diagnostic criteria for KD 112 
had been fulfilled, and if so how to classify the subtype of KD (complete, atypical, or incomplete) for inclusion in the 113 
study.  114 
 115 
Exclusion criteria 116 
Exclusion criteria were patients older than 16 years; outside the pre-defined study period; and those with alternative 117 
final diagnoses. In addition, for the first year of the study, those with streptococcal infection were excluded, but not in 118 
the second year of study, since it is now recognized that streptococcal infection (and other infections) may be 119 
associated triggers for responses resulting in KD 21.  120 
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 121 
Cardiac involvement 122 
We defined coronary artery aneurysms (CAA) as Z score of ≥ 2.5 internal diameter 22. The Z scores were checked 123 
or completed, using Cardio Z software, based on the data supplied by Dallaire and Dahdah 23. Those with 124 
aneurysms were referred to as CAA+ and those without were CAA-. In addition, there were some children with 125 
bright coronary artery walls, dilated (but non-aneurysmal) coronary arteries, pericardial effusion, or myocarditis. 126 
These were recorded as cardiac involvement, but not CAA. We recorded the early presence of CAA at diagnosis, 127 
and also in some cases later echocardiographic data was also presented. Giant aneurysms were defined as 128 
≥8mm or z score ≥10 24. 129 
 130 
DURATION OF THE STUDY 131 
In accordance with the most recent BPSU methodology, data collection was over a 25-month period, Jan 2013 – 132 
Feb 2015. All data was collected and retained in accordance with the Data Protection Act 1998. 133 
 134 
DATA MANAGEMENT, ANALYSIS AND SECURITY 135 
As approved by the ethics committee, parental consent was not obtained as the identity of the cases was known 136 
only to the reporting clinician. Anonymous questionnaires were sent from our study centre after case notification. 137 
Use of the NHS number and date of birth allowed checks for duplication. Using the first four components of the 138 
postcode, the population density was estimated by area where each patient lived in the UK and by area in Ireland. 139 
As most of the data were categorical or not normally distributed, statistical methods based on the Chi-squareds 140 
test were used., or Pearson coefficient as appropriate. Statistical analysis was undertaken at Herriot- Watt 141 
University (MD, RS) using SPSS, version 24. A p value of <0.05 was considered significant. The distribution of 142 
numerical values was summarized as medians and ranges; the Wilcoxon-Mann-Whitney test was used for group 143 
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comparisons of those with or without CAA. A complex System Level Security Protocol (SLSP) was utilized and 144 
was risk assessed on an annual basis. 145 
 146 
ETHICAL APPROVAL 147 
National Research Ethics Committee  11/SW/0310 148 
NHS Sponsorship   CS/2011/3847 149 
 150 
Funding. Kawasaki disease parent support group; and discretionary institutional academic funds from each of the 151 
authors.  152 
 153 
RESULTS 154 
Between 1 January 2013 and 28 February 2015, 601 reports of KD were received by the BPSU, with 38 duplicates, 155 
9 other diagnoses and one with no clinical information. Of the remaining 553, there were 389 cases of complete 156 
KD; 46 atypical cases with fewer than four clinical features but with abnormal echocardiograms; and 116 cases 157 
of incomplete KD. Two cases were diagnosed retrospectively at post-mortem without any clinical data to allow 158 
KD-subtype categorisation (Table 1).   159 
 160 
Males comprised a significantly greater proportion of the cases, and the proportion of Black and Asian patients 161 
was increased relative to the expected proportion of these groups in the population (Table 1) 19. There were 162 
significantly more children under 1 year old with atypical or incomplete KD (45/95; 47%), compared with children 163 
over 1 year old (102/428; 24%) (Chi- squared = 21.31 p<0.0001).  164 
 165 
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The annual incidence was estimated using the 257 cases that had been diagnosed between 1 February 2014 and 166 
31 January 2015, and whose ages were reported since only in the second year were all sub-types of KD reported. 167 
The age-specific annual incidences were 4.55/100,000 at age 0-4 years; 1.26/100,000 at 5-9 years, and 168 
0.08/100,000 at 10-14 years.  169 
 170 
Date of diagnosis 171 
Based on 479 cases reported between1st February 2013 and 31st January 2015, more cases occurred in the 172 
winter (defined as December – February) and spring (March - May) than in the summer (June - August) and 173 
autumn (September – November) months (Figure 1) (Chi-squared tests for monthly and seasonal variations were 174 
significant at 2 p=<0.081). These results controlled for length of month and confirmed the appreciable peaks in 175 
January in both ‘all’ and ‘complete’ cases. 176 
 177 
Time to first point of clinical contact and diagnosis 178 
443 (80%) children saw a general practitioner (GP) at median (range) 2 (0-27) days from the first onset of 179 
symptoms. The time from first GP consultation to hospital admission was 1 (0-32) days; time from disease onset 180 
to formal diagnosis was 7 (0-36) days; and time to diagnosis following admission to hospital was 1 (0-25) days, 181 
with 50 cases being diagnosed on day of admission.  182 
 183 
We used the first four components of the postcode of patients in the UK to assign cases as resident in Urban or 184 
rural areas and compared the proportion of cases occurring in rural or urban areas. Relative to the population 185 
density we found significantly more cases occurring in rural areas (applying a non-linear cubic regression offered 186 
best fit with R2 = 0.867, F=30.290Pearson’s Correlation Test= -0.691, p<0.0051) (Figure 2).  187 
 188 
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CLINICAL FEATURES 189 
Coronary artery status 190 
The results of the initial echocardiograms were available for 523/553 children. There were 11 children in whom 191 
the weights and Zz scores were missing, so these have been omitted from analysis. Overall, 123/512 (24%) had 192 
abnormal coronary Z score (Z score >2) at echocardiography within 30 days of diagnosis. Of these, 95/512 had 193 
coronary Z score ≥ 2.5, thus the overall CAA rate within 30 days of diagnosis was 19%.  194 
In 25 children, there was a pericardial effusion recorded, and in 7 there was either valve regurgitation or depressed 195 
ventricular function. Taking these into account, the all-cardiac complication rate (coronary Z>2, or any other 196 
cardiac complication) was 28% within 30 days of diagnosis (Table 2). It is of note that a much higher proportion 197 
of children under the age of 1 year had CAA+ (39%) compared with those over the age of 1 (13%, p<0.01). 198 
Overall, 8/512 cases (1.6%) developed giant CAA, and 4/86 cases (5%) under 1 year of age had giant CAA. 199 
 200 
Variables associated with coronary artery aneurysms 201 
We reviewed the association of CAA status with features highlighted in previous publications (Table 3) to 202 
determine whether there were any associations with CAA 25 26. In addition, we explored if there were any 203 
differences in coronary outcomes between 2013 and 2014, which may have been influenced by the publication 204 
of a new UK clinical guideline paper at the end of 2013 1. In 28 cases, we did not know the coronary artery status; 205 
and in both of the post mortem cases there were coronary artery aneurysms.  206 
 207 
The presence of fever plus four diagnostic features of KD at the time of diagnosis (complete KD) was associated 208 
with a lower rate of coronary artery involvement. Younger age at presentation; longer time to receive treatment; 209 
and presentation between December and May were all associated with increased risk of CAA. Additional factors 210 
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associated with the presence of CAA were lower albumin, and higher corticosteroid use in those with CAA (Table 211 
3).   212 
 213 
Treatment with IVIG and aspirin 214 
Excluding the 2 cases diagnosed after death, and excluding the 20 cases with incomplete data, 502/531 received 215 
IVIG (95%), with the recommended dose of 2g/kg (97%). 29/531 (5%) did not receive IVIG: 20 with complete KD; 216 
0 with incomplete KD; and 8 with atypical KD, (one not classified). The usual reason for not giving IVIG was 217 
delayed diagnosis, but in one case the parents refused therapy (Table 3). Anti-inflammatory dose aspirin (30-50 218 
mg/kg/day, divided into four daily doses) was given to 472/537; 41 did not receive any aspirin; data regarding 219 
aspirin were missing for the other cases. Following this, an anti-platelet dose of aspirin (3-5mg/kg once a day) 220 
was given to 460 (83%) children. As shown in Table 4, the proportion of patients with CAA was lowest in those 221 
treated with IVIG within 7 days of onset and increased progressively in the group treated between 7 and 10 days 222 
and above 10 days.  223 
 224 
Adjunctive therapy 225 
Overall, corticosteroids were used in 49/512 (10%) cases where CAA status was documented, either as primary 226 
adjunctive (4.6%), or as late rescue therapy (4.8%) (Table 3). Infliximab was given to 10/551 cases (1.8%). Many 227 
children were commenced on antimicrobials (n=73) before the diagnosis of KD was made. No other treatments 228 
were reported. 229 
 230 
Other outcomes  231 
Of the 523 cases with echocardiography performed within 30 days of diagnosis, data on follow up 232 
echocardiography beyond 30 days were available in 49/523 of which 40/49 had persistent CAA. Overall, 8/49 had 233 
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persistent giant CAA, including the 4 cases of giant CAA under the age of 1 year. Three had arthralgia, one had 234 
anaemia, one had hypertension, and one had lethargy. In addition to the 2 cases who were diagnosed after death, 235 
a third child with pre-existing neurological disease died from intractable seizures, providing an all-cause mortality 236 
rate of 3/553 (0.54%), and mortality directly attributable to KD of 2/553 (0.36%). 237 
 238 
 239 
DISCUSSION 240 
This prospective UK population-based study shows that the incidence of KD as reported by paediatricians in the 241 
UK and Ireland has risen since the last survey in 1990 (from 3.4 to 4.55/100,000 children under 5 years, with 242 
male: female ratio of 1.51:1. It is noteworthy that estimates of KD incidence based on hospital admission or GP 243 
database statistics previously reported more than double the number of cases in our survey 8 27. This BPSU 244 
survey used rigorous diagnostic criteria to ensure accurate case inclusion. In contrast hospital admission data are 245 
not based on strict epidemiological KD case definitions, usually relying on diagnoses assigned by junior doctors 246 
or coding clerks and are thus likely to significantly over-record KD cases. Conversely, the voluntary reporting 247 
system used by the BPSU could under-record cases, as busy paediatricians may not respond or recall all the 248 
cases or may believe their colleagues are doing the reporting.  Therefore, our BPSU data are likely to provide a 249 
minimum estimate of annual incidence. Many features observed in this UK and Ireland study are also seen in 250 
studies from other countries, including the majority of cases being less than 5 years old, seasonal occurrence with 251 
more cases in winter and spring, and increased proportion of Chinese or Japanese Asians and Black Africans 252 
relative to their proportion in the general population. We found an increased proportion of cases lived in rural 253 
areas relative to the population distribution. Early (within 30 days) all-cardiac complication rates for this unselected 254 
treated UK population were 28%; 19% had CAA at 6 weeks, based on a coronary Z score ≥2.5 (Table 2). 255 
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Worryingly, 39% of KD patients under 1 year of age developed CAA despite IVIG; and mortality rates at 0.36% 256 
were approximately 10-fold lower than the last BPSU study.  257 
 258 
We were surprised that residence in urban areas was associated with lower incidence of KD than rural residence. 259 
There might be many different explanations for this finding, including greater exposure to toxins used in farming, 260 
agriculture associated microorganisms, or increased exposure to pollens 3. The suggestion that wind patterns 261 
could propagate triggers might be of relevance in this context 6. 262 
There was a change in the case ascertainment protocol from the first year of the study to the second. We were 263 
obliged by the BPSU reporting restrictions to have a small number of cases (less than 300 in each year) and there 264 
was concern that including all cases of KD would make the total number too large. However, it was clear, during 265 
the first year of study, that we were being notified of incomplete cases and that we were not going to exceed 300 266 
cases per year. In addition, there was a new guideline that was published during the time of the study advising 267 
steroids in high risk cases. We wished to capture both of these pieces of information.  268 
Clearly, the incidence of all cases of KD could therefore only be based on the second year of study. Despite this, 269 
we saw little difference in the demographics between the two years. 270 
We found that the frequency of early CAA (19%), is lower than the 29% observed in the treated cases in the 271 
original 1990 BPSU study13,  but significantly higher than CAA rates previously reported from other countries24 272 
and comparable to reported coronary sequelae rates for untreated cases 1 18. This adds weight to our belief that 273 
the rise in observed incidence is not due to better case ascertainment, but due to a real increase in nu,mber of 274 
cases and also case severity.  Similarly high CAA rates have now also been observed in Sweden [ref] and Russia 275 
[ref], with delayed diagnosis cited as a likely explanation for high coronary complication rates in the latter study. 276 
We found that the proportion with CAA was lowest in patients treated within 7 days, and this increased with later 277 
treatment.  Our data therefore strongly suggest that delayed diagnosis and treatment is a significant factor 278 
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contributing to the high incidence of CAA in the UK. Furthermore, the low numbers of patients receiving adjunctive 279 
treatments such as corticosteroids or anti-TNF, which are associated with  more rapid resolution of inflammation 280 
and reduced CAA risk, suggests many UK KD patients are not receiving optimal therapy advised in national and 281 
international guidance 1. 282 
 283 
Our study confirms that children under 1 year are more likely to have atypical KD and higher rates of coronary 284 
sequelae (39%), as reported in other series 1. Diagnosis of KD is difficult in the absence of all the typical features. 285 
As a high proportion of infants under 1 year of age do not fulfil the KD diagnostic criteria, there is a need for 286 
increased awareness of the possibility of KD in any infant with evidence of persistent inflammation (raised CRP, 287 
ESR or white cell count) and no response to antibiotics. In these infants, echocardiography is an urgent 288 
investigation required as part of the diagnostic work up of suspected incomplete KD. A high index of suspicion is 289 
thus required, and early treatment with IVIG and additional anti-inflammatory agents, and referral to specialist 290 
units for suspected atypical KD cases in view of the high risk of CAA is advised. Our findings also support the 291 
previous suggestion that children under 1-year should be regarded as high risk for coronary sequelae 1, and 292 
therefore be targeted for more aggressive primary treatment. It is also of note that there was a higher rate of CAA 293 
in children in the second half of the study, after 1.2.2014. The most likely reason for this is that we included 294 
atypical KD in the second half of the study, which have CAA by definition. 295 
 296 
Ninety-four % of children received IVIG in line with current guidance along with high dose aspirin in almost all, 297 
although as previously highlighted, those children with CAA+ were treated later (median 10 days) than those 298 
without CAA (7 days), highlighting the importance of instituting treatment as early as possible (i.e. not just within 299 
10 days) to improve outcomes 28.   300 
 301 
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Corticosteroids were only used in 10% of cases (Table 3); 4.6% of cases as primary therapy, and as rescue 302 
therapy in 4.8%. This overall relatively low use of corticosteroids, combined with delay in initiating treatment, could 303 
explain the high CAA rates we observed since a recent meta-analysis of 2746 patients has now demonstrated 304 
that early addition of corticosteroids is associated with reduced risk of CAA compared with IVIG therapy alone, 305 
particularly for high risk cases (odds ratio 0.424; 95%CI, 0.270-0.665) 28. Arguably, however, all UK KD patients 306 
could be deemed “high-risk”, since 19% developed CAA within 30 days despite IVIG treatment, with even higher 307 
risk for children under the age of 1 year, of whom 39% developed CAA, of which 5% had giant CAA with poor 308 
prognostic outcomes. We would have liked to have had follow-up on the CAA after 30 days, but we were obliged 309 
by our protocol approval by the BPSU and National Information Governance, to keep this within the acute phase. 310 
We hope to be able to return to these patients and obtain ethical approval and consent for a follow-up study in 311 
the future. 312 
 313 
Limitations. 314 
BPSU methodology relies on busy doctors to complete data entry, and thus aA surveillance-based study of this 315 
nature is limited since it is entirely dependsent on the entry of data and case ascertainment for completeness. 316 
Therefore, although ours was Although a prospective study, it is expected that there will be a small proportion of 317 
cases that are not reported as evidenced in a recent German study suggesting that up to 44% of cases can be 318 
missed 29. This will only serve to increase the incidence of KD above that in the present reported study. Also, but 319 
by the nature of BPSU study methodology, follow up data examining late cardiac sequelae are limited. 320 
 321 
CONCLUSIONS 322 
KD has a rising incidence in the UK and Ireland, and cardiac sequelae are higher than reported for other countries 323 
despite most patients receiving IVIG therapy. Treatment delay is likely to have been contributory to high CAA 324 
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rates. A future National UK comparative clinical trial of corticosteroids as primary adjunctive therapy for unselected 325 
KD patients is now planned. In the meantime, general practitioners and paediatricians should be aware that 326 
treatment to completely ablate systemic inflammation as early as possible is required to prevent lifelong cardiac 327 
sequelae, and that the historic KD therapeutic adage of “treatment within 10 days” is no longer fit for purpose.    328 
 329 
WHAT IS ALREADY KNOWN ON THIS TOPIC 330 
1. Kawasaki Disease is the commonest acquired heart disease in the western world, with highest incidence in 331 
North East Asians and with unknown aetiology. 332 
2.  Seasonal variation, with peaks in winter and spring, and reported epidemics suggest that there are 333 
environmental factors, which trigger the condition.   334 
3. The original BPSU study in 1990 suggested that UK patients might have high CAA rates despite IVIG. 335 
 336 
WHAT THIS STUDY ADDS 337 
1. There is a rising incidence of KD compared to 1990, with increased incidence in Chinese and Japanese Asians, 338 
and in children of Black African descent; and increased incidence in rural populations. 339 
2. Children under 1 year are at highest risk of CAA (39%) and are more likely to present with atypical KD.  340 
3. The overall frequency of CAA remains high at 19% despite more widespread use of IVIG, although mortality is 341 
now 10-fold lower than documented in 1990. Late diagnosis and treatment is associated with coronary artery 342 
aneurysms.  343 
 344 
 345 
  346 
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Figure legends 347 
 348 
Figure 1. Incidence of KD by month at diagnosis, showing breakdown into complete, atypical and incomplete 349 
cases. PM was diagnosis at post-mortem.  350 
 351 
Figure 2. Plot of urbanicity (as assessed by population per postcode, per sq km) against number of cases of 352 
KD. 353 
 354 
 355 
 356 
  357 
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Table 1. The demographics of Kawasaki disease in the UK and Ireland. 358 
 359 
 360 
  361 
 
Complete Atypical Incomplete 
Post-
mortem 
Total 
Total No 
of cases 
 
389  % 46 %  116 %  2 %  553 100% 
Sex Male 231 60% 28 61% 64 55% 0   323 59% 
 Female 153 40% 18 39% 42 36% 2 100% 215 39% 
 Sex unreported 5 1% 0 0% 10 9% 0   15 3% 
 Male:Female ratio 1.50:1   1.56:1   1.52:1   0   1.51:1   
Age 
(years) 
<1 
50 13% 20 43% 25 22% 2 100% 97 18% 
 1-4 251 64% 19 41% 48 41% 0   318 57% 
 5-9 69 18% 5 11% 28 24% 0   102 18% 
 10-16 7 2% 1 2% 1 1% 0   9 2% 
  Not reported 12 3% 1 2% 14 12% 0   27 5% 
Ethnicity White 257 75% 26 70% 71 72% 1 50% 355 64% 
 White & Black 12 6% 4 5% 4 2% 0   20 7% 
 White & Asian 10 2% 1 2% 3 0% 0   14 2% 
 Black 39 3% 4 6% 3 0% 0   46 4% 
 Asian sub-continent 25 7% 5 8% 12 9% 0   42 10% 
 Other Asian  11 5% 1 8% 3 7% 1 50%  16 8% 
 Chinese/Japanese 14 3% 4 2% 2 9% 0   20 5% 
 Others 21 5% 1 2% 18 16% 0  40 7% 
Country  Scotland 19 5% 3 7% 7 6% 0   28 5% 
 Republic of 
IrelandEire 
23 6% 0 0% 9 8% 0   31 6% 
 Wales 24 6% 7 15% 6 5% 0   35 6% 
 N. Ireland 9 2% 0 0% 2 2% 0   12 2% 
 IoM/JerseyChannel 
Islands 
2 1% 2 4% 1 1% 0  5 1% 
 England 312 80% 34 74% 94 79% 2 100% 442 80% 
Date of 
illness 
1.2.13-31.1.14 
186 49% 13 28% 27 25% 0   226 42% 
 1.2.14-31.1.15 161 42% 30 65% 70 60% 2 100% 263 49% 
 Outside study period 36 9% 3 7% 9 8% 0   48 9% 
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Table 2. Echocardiographic data showing Cardiac complications. There were 11 children in whom the weights 363 
and z scores were missing, which have not been included in the table. 364 
Time of 
Echo 
Number 
assessed 
Coronary
z<2 
Coronary
2≤z<2.5 
Coronary 
2.5≤z<5 
Coronary 
5≤z<10 
Coronary 
z≥10 
Pericardial 
Effusion 
Valve 
regurgitation 
At Diagnosis 523 389 28 59 28 8 25 7 
>30 days 49  9 20 12 8 0 0 
 365 
 366 
Table 3:  Association of coronary artery status with individual variables. CAA+ = those with coronary artery 367 
aneurysms. CAA- = those without aneurysms. IVIG = intravenous immunoglobulin. P P value is difference in 368 
median: ns = not significant. The numbers of patients receiving corticosteroids were too small for meaningful 369 
statistical testing. There were 11 children in whom the weights and z scores were missing, which have not been 370 
included in the table.  371 
Criterion CAA+ (n=95) CAA- (n=417) P value 
Male 62 (69%) 247 (59%) 0.27 ns 
Median lowest Albumin g/L 
Range 
26 
(13, 41) n=83 
31 
(21, 49) n=372 
0.049 
Median Lowest Sodium mmol/L 
Range 
134 
(125, 142) n=48 
134 
(123, 141) n=210 
0.92 ns 
Median Lowest Platelet count x109/L 
Range 
212 
(30, 442) n=95 
245 
(54, 450) n=415 
0.15 ns 
Median Age months at presentation 
Range 
21.6 
(2.4, 190.0) n=93 
36.0 
(1.2, 190.0) n=409 
0.005 
Median Time to treatment (days) 
Range 
10.0 
(2, 37) 
7.0 
(1, 36) 
0.005 
Mucosal involvement at diagnosis 77/95 (81%) 360/416 (87%) 0.19 ns 
Dec-May presentation 64/95 (67%) 245/416 (59%) 0.12 ns 
Presentation before 1.2.2014 53/95 (56%) 210/416 (50%) 0.35 ns 
Primary steroid use 11/95 (12%) 13 (3%)  
Late corticosteroid use 13 (14%) 12 (3%)  
No corticosteroid use 67/92 (73%) 359/384 (93%) 0.03 
 372 
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 374 
 375 
 376 
Table 4: Association of time of treatment with Intravenous immunoglobulin (IVIG) with coronary artery aneurysms. 377 
Numbers were small, so statistical comparison of these groups was not performed. Absolute numbers with % in 378 
brackets 379 
 380  
Age <1 year Age >1 year 
IVIG timing Number 
of cases 
Z<2.5 Z≥2.5 
  
missing cases Z<2.5 Z≥2.5 missing 
IVIG before day 7 45 33 11 1 160 138 17 5 
IVIG day 7-10 28 12 15 1 142 116 23 3 
IVIG>day 10 14 3 9 2 79 62 15 2 
No IVIG or missing 8 4 2   49 41 1   
 381 
 382 
 383 
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